The critical role of tumor necrosis factor (TNF) as a mediator in autoimmune inflammatory processes is evident from in vivo studies with TNF-blocking agents.
pathology in rheumatoid arthritis and .Crohn disease and in animal models like experimental autoimmune encephalomyelitis is unclear. Possibilities include regulation of vascular adhesion molecules enabling leukocyte movement into tissues or direct cytokine-mediated effector functions such as mediation of tissue damage. Here we show that administration of a TNF receptor (55 klDa)-IgG fusion protein prevented clinical signs of actively induced experimental autoimmune encephalomyelitis. Significantly, the total number of CD4+ T lymphocytes isolated from the central nervous system of clinically healthy treated versus diseased control animals was comparable. By using a CD45 congenic model of passively transferred experimental autoimmune encephalomyelitis to enable tracking of myelin basic protein-specific effector T lymphocytes, prevention of clinical signs of disease was again demonstrated in treated animals but without quantitative or qualitative impediment to the movement of autoreactive T lymphocytes to and within the central nervous system. Thus, despite the uninterrupted movement of specific T lymphocytes into the target tissue, subsequent disease development was blocked. This provides compelling evidence for a direct effector role ofTNF/lymphotoxin a in autoimmune tissue damage.
Studies in animal models of autoimmune disease have implicated tumor necrosis factor (TNF)/lymphotoxin (LT) a in their pathogenesis (1) (2) (3) (4) (5) (6) . That TNF plays a role in a human autoimmune disease was recently demonstrated in clinical trials in which rheumatoid arthritis patients showed significant clinical improvement following treatment with cA2, a chimeric TNF-specific monoclonal antibody (mAb) (7, 8) . Precisely how TNF is involved in the disease process remains ill-defined, but mechanisms could include the induction of major histocompatibility complex molecules on the surface of tissue cells in concert with other cytokines (9, 10), upregulation of adhesion molecules resulting in enhanced effector cell movement into tissue sites (11) (12) (13) , and direct cytotoxicity (14, 15) . Experimental evidence suggesting one action to be of overriding importance is lacking. Nevertheless, the virtual absence of inflammation after administration of anti-TNF/LT antibody, for example, in the central nervous system (CNS) in experimental autoimmune encephalomyelitis (EAE) has lead to the proposal that the primary block in this disease process may be prevention of adhesion molecule upregulation (16) . Likewise, EAE prevention by administration of a mAb to interleukin 12 (17) was assumed to involve modulation of integrin adhesion function based on the similarities between the kinetics of disease inhibition with anti-interleukin 12 mAbs and anti-a4131 integrin mAbs (18) .
Here we have used as a TNF antagonist a recombinant version of the 55-kDa human TNF receptor (TNFR) fused to human IgG (TNFR-IgG), a molecule shown previously to bind and efficiently inhibit mouse TNF (19) . The advantages of these fusion protein reagents for experimental studies, in contrast to species-specific anti-TNF mAb, include binding of TNF from all species (there are no rat TNF-specific mAbs available) and substantially greater TNF neutralizing capacity and half-life in vivo compared with monovalent TNFR molecules (20) . By using this TNF antagonist to treat rats with EAE elicited by immunization with myelin basic protein (MBP) in adjuvant, a profound inhibition of the signs of clinical disease was obtained, but inflammation into the CNS remained substantial. By employing a model of EAE that enables tracking of autoreactive T cells to the CNS, we have explored the mechanism of disease inhibition in such TNFR-IgG-treated animals. Our data provides compelling evidence that tissue damage in an autoimmune disease is attributable to a direct effector role of TNF/LT and not solely to TNF/LT-induced recruitment of immune cells to sites of inflammation.
MATERIALS AND METHODS
Animals, Cell Isolation Procedures, and Flow Cytometry. Eight-to 10-week-old female or male rats were used. Lewis and PVG-RT7a (CD45a) rats were obtained from the Animal Resources Center (Perth, Australia) or bred in local facilities (Blackburn, University of Sydney). Major histocompatibility complex identical PVG-RT7" (CD45b) rats congenic for an alternative allotype of the rat RT7/leukocyte common antigen molecule were bred and housed in the Centenary Institute animal facility. All animal procedures were approved by The Animal Care and Ethics Committee of the University of Sydney. CNS-associated leukocytes and microglia were isolated as described (21, 22 Induction of EAE and TNFR-IgG Treatment. Actively induced disease was elicited in Lewis strain rats by injection of MBP in complete Freund's adjuvant (23) , with signs of disease appearing 10-12 days after immunization. Short-term encephalitogenic MBP-specific CD4+ T-cell lines were derived from immunized PVG rats as described (24) , and EAE was passively transferred to naive (nonirradiated) recipient rats after the second round of in vitro antigenic (MBP) restimulation of these T cells. At the time of transfer, the magnitude of T-cell proliferation to MBP was 90% of that to concanavalin A, illustrating that most cells were MBP-specific. (26) . Five hundred units of recombinant mouse TNF or undiluted activated rat T-cell supernatant (no recombinant rat TNF was available for testing) killed 100% and 50% of cells, respectively, and this was blocked to 80-90% in both cases by addition of 1 ng of TNFR-IgG. Five nanograms of TNFR-IgG virtually prevented all cell lysis (data not shown).
TNFR-IgG Inhibits Actively Induced EAE Without Preventing Inflammation. Clinical signs of actively induced EAE in highly susceptible Lewis rats were ameliorated substantially by administration of TNFR-IgG (3 mg per rat) just prior to onset of disease (which occured 11-12 days after immunization; Table 1 ), consistent with a recent study in mice employing this same reagent (27) 20 days after T-cell injection despite discontinuation of treatment at day 5. Our ability to assess animals over the longer term is limited by animal ethics considerations.
Analysis of donor and host-derived cells isolated from the CNS of PVG CD45-congenic TNFR-IgG-treated and mocktreated rats from the earliest signs of disease (day 4) to recovery (day 7) was highly informative. Fig. 2 shows flow cytometric plots of day 4, as these illustrate most clearly the early effects of TNFR-IgG treatment, and in Fig. 3 , a quantitative analysis of cell recoveries from this and later time points is shown. Dual staining with pan-CD45 mAb [recognizing resident host CNS macrophages (microglia) and donor and host inflammatory cells] and anti-CDllb/c mAb (Fig. 2 Upper) revealed four populations (1-4; see legend for details). The salient points to note are that there are relatively more inflammatory cells in control rats compared with TNFR-IgGtreated animals (quadrants 3 and 4). However, staining for the a/3 TCR shows that the majority of populations 3 and 4 in TNFR-IgG-treated rats (Fig. 2D ) are T cells (population 5) while in controls (Fig. 2C) , only a proportion are T cells (population 5); the remainder are non-T cells (population 6). The latter are not macrophages, since they are mostly CD11b/c-( Fig. 2A) , and also are not MBP-reactive T cells that have downregulated their a/3 TCR after antigenic interaction. That is, in three-color analysis (see below) all cells displaying the donor CD45 allotype in treated and untreated rats were found to express the af TCR at levels well above background. Preliminary studies indicate that population 6 ( Fig. 2C) is a complex mixture of cells, many staining with the mAb 3.2.3, a reported natural killer cell marker (30) . However, the bulk of the cells also lack CDllb/c ( Fig. 2A) , but it is possible that natural killer cell expression of this may depend on the activation state of the cells or their locality (for example, downregulating CD1lb/c as they move into tissues). The main point to stress is that early in the disease process, there is no apparent impediment to the initial influx of T cells in the presence of TNFR-IgG, but the early nonspecific (as yet to be classified) inflammatory response has been blunted substantially. day 6 day 7 The origin of the CNS T-cell response in TNFR-IgG-treated rats was analyzed by three-color flow cytometry (Fig. 3) , and the results revealed that the number of MBP-specific T cells in the CNS of control vs. TNFR-IgG-treated rats was very similar, particularly at day 4 but also at day 7. At the height of disease (day 6), control animals had about twice as many MBP-specific T cells as TNFR-IgG-treated rats, almost certainly representing self-recruitment as a result of tissue damage. The number of non-T inflammatory cells was generally higher in control rats, particularly evident at day 4, and this is also true for nonspecifically recruited T cells (from the host, CD45b+). A higher number of MBP-specific T cells (that is, 1 X 107 cells vs. 5 X 106, culled day 7) was administered to some animals to examine whether disease prevention by TNFR-IgG was simply an effect of reducing MBP-specific T-cell numbers below a critical threshold. This was not the case because high cell numbers were recovered (e.g., Fig. 3 Lower), and, despite a slightly increased weight loss in TNFR-IgG-treated rats, still no disease could be detected. Untreated animals, in contrast, showed more severe and extended clinical signs including incontinence and paralysis of the hind legs (up to disease score 3.5; data not shown). A consistent trend in all studies in actively or passively-induced EAE in the PVG-congenic system or in Lewis rats was the more rapid loss of T cells from the CNS of control rats during the recovery phase of disease (for example, Fig. 3 , huIgG vs. TNFR-IgG at day 7). This was most evident in the MBP-specific donor T cells and could represent delayed apoptotic loss of specific T cells in the CNS, for which good evidence now exists (31) . The implication is that TNFR-IgG arrests this effect in some way. Further studies with larger animal numbers are required to determine if this trend is a statistically significant one.
Specific T-Cell Movement in the CNS Is Normal. Potentially, the distribution of MBP-specific T cells within the CNS could affect their ability to cause damage and disease. Staining for donor MBP-specific T cells (Fig. 4) at two sites in the CNS (the medulla and spinal cord) revealed no apparent difference in cell distribution between huIgG-treated control rats with EAE ( Fig. 4A) and healthy TNFR-IgG-treated control rats (Fig. 4 B and C) . In particular, there is significant movement of MBP-specific T cells into the CNS parenchyme in both control (Fig. 4A ) and treated rats (Fig. 4 B and C) (1995) in addition to CD4+ T lymphocytes (see Table 1 legend). Thus, the first mechanism is the favored one.
Why the disparity between these data and those using anti-TNF antibodies? Two possible explanations are binding specificity and lytic capacity. In addition to binding soluble TNF and LT a, our preliminary results suggest that the TNFR-IgG molecule can bind the cell surface transmembrane form of TNF. The major form of surface LT, having the stoichiometry a112, does not bind the 55-kDa or 75-kDa TNFRs but uses an alternative receptor (35) . It is possible that the anti-TNF antibodies that blocked inflammatory cell infiltration could bind to the major form of surface LT and this binding modulated inflammation. Although a possible scenario, it seems unlikely, nevertheless, that this could in itself account for the difference between the antibody and TNFRIgG studies. A more plausible explanation is that lytic anti-TNF antibodies (raised in rabbit, hamster, etc.) may bind to the surface form of TNF or LT on activated T cells, leading to cell death. Some lytic anti-CD4 antibodies, for example, inhibit tissue-specific autoimmune inflammatory disease in this way (36, 37) . Thus, the lack of adhesion molecule upregulation could reflect the fact that there are reduced numbers of activated, TNF-expressing MBP-specific T cells to elicit it and not that TNF-mediated adhesion molecule upregulation has been prevented directly. The continued ability to isolate proliferating or autoreactive T cells from lymphoid tissue of anti-TNF antibody-treated animals (2, 27) does not argue against this possibility as the transient nature of very high levels of surface TNF expression after T-cell activation (38) may render many cells resistant to lysis. Although the ability of TNFR-IgG bound to surface TNF to trigger cell lysis in vivo is not known for any species and indeed could be different between species, recent in vitro studies comparing the capacity of the TNFR-IgG used in these studies and anti-human TNF cA2 antibody to lyse targets expressing surface TNF (human) clearly indicate the potent lytic potential of cA2 (39) while TNFR-IgG is -3 times less efficient (B.J.S., unpublished data). The localization of high numbers of MBP-specific T cells in the CNS of treated rats in the present study (Figs. 3 and 4) is consistent with this.
Because little is known about the role of LT a in autoimmune disease, and because the TNF antagonist used in this study inhibits soluble LT a as well as TNF, it is not clear whether inhibition of LT a contributes to EAE disease amelioration. In the light of promising clinical data using TNFspecific mAbs to treat two different inflammatory diseases (8, 40 ) and the major role of surface LT in lymphoid tissue modeling (41) , it seems likely that TNF and not LT a is the primary mediator in the EAE model. This suggests, furthermore, that TNF-specific reagents may prove beneficial for patients with multiple sclerosis.
In conclusion, by virtue of the observation that EAE can be prevented by inhibiting TNF function, but without blockade of T-cell movement into tissues, these studies provide the strongest evidence yet for the role of TNF as a direct effector molecule in the induction of autoimmune pathology. Nevertheless, the actual mechanism of disease inhibition by TNFRIgG remains unresolved, but one avenue to be explored is that in addition to blocking the effect of preformed surface/ secreted TNF, this treatment also affects the further production of pathogenetically relevant cytokines (TNF as well as others) by encephalitogenic MBP-specific T cells entering the CNS.
